All attendees shared a vested interest in the rapidly evolving cancer treatment landscape. Nowhere was the vastness of that ...

From cancer immunotherapy to diabetes and weight loss breakthroughs, 2025’s top-selling drugs highlight how pharmaceutical ...

As drug development increasingly targets multiple indications, pharma companies must make strategic branding ...

Summit Therapeutics Inc. (NASDAQ:SMMT) ranks among the 30 stocks expected to beat the market by 20 percentage points this ...

Breaking down what patients should know about each FDA therapeutic approval from June 2025 across various oncology ...

Recent FDA decisions added new options for dermatologists involved in treating patients with psoriasis, bullous pemphigoid ...

Three major Mount Sinai research studies offer new hope for patients facing chronic lymphocytic leukemia (CLL), a rare type ...

Alongside her husband, Bob Duggan, Maky Zanganeh has guided cancer drug developer Summit Therapeutics to reach staggering new ...

Merck faces a looming challenge with the 2028 patent expiration of Keytruda, but it’s not sitting around twiddling test tubes ...

Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically ...

Merck's growing pipeline, with nearly 20 new launches ahead, is set to reshape its portfolio as Keytruda's 2028 patent expiry ...

Merck’s stock just broke above its 50-day simple moving average, signaling a potential short-term bullish trend despite ...